En español

Chemistry and Pharmaceutics Branch (CPB)

What We Do:

The Branch supports research in the areas of medicinal chemistry, analytical chemistry, metabolism, pharmacokinetics and pharmacodynamics, pharmacogenetics and pharmaceutics/formulation development aimed at the design, evaluation and development of medications for the treatment of drug addiction.

The CPB supports research and provided services in support of clinical development in the following areas:

  • Medicinal chemistry for the design and synthesis of new chemicals and structural classes with therapeutic potential including the applications of molecular modeling, structure-activity relationships, combinational techniques, and natural product approaches.
  • Pharmaceutics for the design and development of new dosage forms to improve their therapeutic effectiveness and/or to minimize the abuse potential of potential treatment medications.
  • Pharmacokinetics (PK) and pharmacodynamics of potential treatment medications.
  • Pharmacogenetics to investigate the genetic variability affecting pharmacokinetics.
  • Bioanalytical method development for quantifying treatment medications/metabolites, abused drugs and endogenous substances (as biomarkers) in biological fluids.
  • Centralized bioanalytical resources to support PK studies and clinical trials.
  • Bulk chemical synthesis (GMP and non GMP) and clinical dosage forms development and manufacture.
  • Consultation and technical support on the aforementioned capabilities.

Staff Biographies and Research Interests

  • Nora Chiang, Ph.D., - Chief
    Manages activities and resources of the Branch, including medicinal chemistry, analytical chemistry, dosage form development and production, pharmacokinetics, pharmacodynamics, toxicokinetics and metabolism. Over twenty years of research experience within NIDA, two years review experience with the Food and Drug Administration and one year research experience with Ciba-Geigy. Joined DTMC in 1989.
  • Sung Kim, M.D. Health Scientist Administrator
    Plans, directs, and evaluates research.  Manages development and production of new and improved drug products for the treatment of Substance Use Disorders (SUDs).  Assists in the management of the medicinal chemistry program in support of the Addiction Treatment Discovery and Development program.  Twenty-three years of experience in government involving drug development and regulation at the NCI and FDA. Joined DTMC in 2017.
  • Richard (Rik) Kline, Ph.D., - Medicinal Chemist
    Responsible for managing a medicinal chemistry effort in support of the addiction treatment discovery program (ATDP). Manages and integrates chemical database as well as molecular modeling efforts in support of the ATDP. DTMC/NIDA web team liaison. One-year pharmaceutical and two years software development industry experience. Five years academic and government research experience. Joined DTMC in 1998.
  • Phillip Krieter, Ph.D., - Pharmacologist
    Serves as project officer for ADME and Pharmacokinetics for drug abuse treatment programs related to the discovery and development of new medications. Thirty years of experience in drug disposition in pharmaceutical industry. Joined DTMC in 2014.
  • Charles Marschke, Jr., B.S., - Chemist
    Project Officer for maintaining and distributing compounds under evaluation by the addiction treatment discovery program. Assists in the evaluation of novel biochemical approaches to drug treatment. Responsible for providing technical support for maintenance of structure-activity database and submission and tracking of compounds submitted for preclinical testing. Joined DTMC in 1992.
  • Ming L. Shih, Ph.D., - Program Director of Research Grants in Medicinal Chemistry
    Oversees, reviews, and manages a grant portfolio for the synthesis and pre-clinical evaluation of novel chemical compounds for the treatment of drug dependence. Supervises contracts involving analytical methodology for bioanalytical monitoring and illicit drug screening. Twenty years of R & D experience in medication and diagnostic device development in the Department of Defense and 5 years of clinical trial experience in the drug addiction field before joining DTMC in 2005.

This page was last updated November 2017